Carlsson S - Search Results

1

Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.

Carlsson S, Elg M, Mattsson C. Carlsson S, et al. Thromb Res. 2002 Aug 15;107(3-4):163-8. doi: 10.1016/s0049-3848(02)00257-8. Thromb Res. 2002. PMID: 12431484

2

A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays.

Carlsson SC, Mattsson C, Eriksson UG, Sarich TC, Wåhlander K, Eliasson A, Karlson BW, Sheth SB, Held P. Carlsson SC, et al. Thromb Res. 2005;115(1-2):9-18. doi: 10.1016/j.thromres.2004.07.001. Thromb Res. 2005. PMID: 15567447 Review. No abstract available.

3

Mechanism of action of the oral direct thrombin inhibitor ximelagatran.

Mattsson C, Sarich TC, Carlsson SC. Mattsson C, et al. Semin Vasc Med. 2005 Aug;5(3):235-44. doi: 10.1055/s-2005-916162. Semin Vasc Med. 2005. PMID: 16123910 Review.

4

Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat.

Elg M, Börjesson I, Carlsson S. Elg M, et al. Among authors: carlsson s. Biopharm Drug Dispos. 2003 Sep;24(6):251-7. doi: 10.1002/bdd.363. Biopharm Drug Dispos. 2003. PMID: 12973822

5

The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat.

Carlsson S, Elg M. Carlsson S, et al. Blood Coagul Fibrinolysis. 2005 Jun;16(4):245-9. doi: 10.1097/01.mbc.0000169216.70184.8d. Blood Coagul Fibrinolysis. 2005. PMID: 15870543

6

Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat.

Eriksson BI, Carlsson S, Halvarsson M, Risberg B, Mattsson C. Eriksson BI, et al. Among authors: carlsson s. Thromb Haemost. 1997 Nov;78(5):1404-7. Thromb Haemost. 1997. PMID: 9408027

7

Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat.

Elg M, Gustafsson D, Carlsson S. Elg M, et al. Among authors: carlsson s. Thromb Res. 1999 May 1;94(3):187-97. doi: 10.1016/s0049-3848(98)00213-8. Thromb Res. 1999. PMID: 10326765

8

Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.

Elg M, Carlsson S, Gustafsson D. Elg M, et al. Among authors: carlsson s. Thromb Res. 2001 Feb 1;101(3):145-57. doi: 10.1016/s0049-3848(00)00397-2. Thromb Res. 2001. PMID: 11228338

9

Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits.

Elg M, Carlsson S, Gustafsson D. Elg M, et al. Among authors: carlsson s. Thromb Res. 2001 Feb 1;101(3):159-70. doi: 10.1016/s0049-3848(00)00398-4. Thromb Res. 2001. PMID: 11228339

10

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.

Gustafsson D, Nyström J, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K, Ungell A, Sörensen H, Någård S, Abrahamsson A, Bylund R. Gustafsson D, et al. Among authors: carlsson s. Thromb Res. 2001 Feb 1;101(3):171-81. doi: 10.1016/s0049-3848(00)00399-6. Thromb Res. 2001. PMID: 11228340

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

756 results

Search Page

Filters